Jugular Foramen Syndrome

Jugular Foramen Syndrome
Other Names	Vernet Syndrome
T1 MRI with contrast of a glomus jugulare, saggital view
Identifiers
ICD-9	352.6
ICD-10	G52.7
Outside Resources
Radiopaedia	Vernet Syndrome

Overview

Jugular foramen syndrome (Vernet syndrome) is characterized by dysfunction of cranial nerve IX (glossopharyngeal), cranial nerve X (vagus), and cranial nerve XI (accessory) as they traverse the jugular foramen. The syndrome results in ipsilateral paralysis of the soft palate and pharynx, vocal fold paralysis, and weakness of the sternocleidomastoid and trapezius muscles.

The jugular foramen is a complex anatomical structure at the skull base that transmits critical neurovascular structures. Lesions affecting this region can arise from a variety of pathologies including tumors (paraganglioma, schwannoma, meningioma), inflammatory conditions, vascular abnormalities, and trauma.

The term "jugular foramen syndrome" is often used interchangeably with Vernet syndrome. However, when the hypoglossal nerve (XII) is also involved (as occurs with lesions extending to the hypoglossal canal), the condition is termed Collet-Sicard Syndrome.

History

Maurice Vernet (1887-1974), a French neurologist, described the syndrome of isolated jugular foramen involvement with paralysis of cranial nerves IX, X, and XI in 1916. His description distinguished this syndrome from other skull base syndromes involving overlapping cranial nerve deficits.

Historical nomenclature for skull base syndromes can be confusing, as multiple eponyms describe overlapping patterns of cranial nerve involvement. Collet (1915) and Sicard (1917) independently described a related syndrome involving CN IX, X, XI, and XII.

Pathophysiology

Relevant Anatomy

Jugular foramen syndrome is a result of mass effect or injury to the contents of the jugular foramen at the skull base.

Jugular foramen structure:

The jugular foramen is located between the petrous temporal bone and occipital bone. It is divided into three compartments:

• Pars nervosa (anteromedial): Contains CN IX (glossopharyngeal) and inferior petrosal sinus
• Pars vascularis (posterolateral): Contains internal jugular vein and CN X (vagus)
• Pars ossea (intermediate): Contains CN XI (accessory)

Neural contents:

• Glossopharyngeal nerve (IX): Sensory to posterior tongue/pharynx/middle ear; motor to stylopharyngeus; parasympathetic to parotid; carotid body/sinus afferents
• Vagus nerve (X): Sensory to external ear/larynx/pharynx/viscera; motor to pharynx/larynx/palate; parasympathetic to thoracic/abdominal viscera
• Accessory nerve (XI): Motor to sternocleidomastoid and trapezius

Vascular contents:

• Internal jugular vein: Major venous outflow from cranial cavity
• Inferior petrosal sinus: Drains cavernous sinus to jugular vein
• Posterior meningeal artery: Variable contribution

• 

  Skull base foramina with labels

Disease Etiology

Tumors (most common cause):

• Paraganglioma (glomus jugulare): Most common jugular foramen tumor
• Schwannoma: Usually from CN IX, X, or XI
• Meningioma: From dura of foramen
• Metastatic disease: From distant primary

Vascular: Jugular vein thrombosis, internal carotid artery aneurysm, dural arteriovenous fistula

Infectious and Inflammatory: Petrous apicitis, skull base osteomyelitis, sarcoidosis, granulomatosis with polyangiitis

Traumatic: Skull base fractures, penetrating trauma, iatrogenic injury from surgery

Other: Paget disease, fibrous dysplasia, chordoma, chondrosarcoma

Genetics

SDH gene mutations are associated with familial paraganglioma syndromes:

• SDHD: Most common in head and neck paragangliomas; autosomal dominant with paternal transmission
• SDHB: Associated with higher malignancy risk (16-19%); requires close surveillance
• SDHC, SDHAF2: Less common variants

Genetic testing is recommended for all patients with paragangliomas, particularly those with bilateral disease, family history, or age <40 years.

Histology

Paraganglioma: Chief cells (type I) arranged in "Zellballen" (cell nests) surrounded by sustentacular cells (type II); positive for chromogranin A, synaptophysin; S-100 highlights sustentacular cells.

Schwannoma: Antoni A (cellular, organized) and Antoni B (loose, myxoid) patterns; positive for S-100; verocay bodies may be present.

Meningioma: Whorls of meningothelial cells; psammoma bodies; positive for EMA and vimentin.

Diagnosis

Patient History

Symptoms reflect CN IX, X, XI dysfunction:

Glossopharyngeal nerve (IX): Dysphagia, loss of taste on posterior third of tongue, reduced pharyngeal sensation, glossopharyngeal neuralgia

Vagus nerve (X): Hoarseness (vocal fold paralysis), dysphagia, aspiration, nasal regurgitation, reduced laryngeal sensation

Accessory nerve (XI): Difficulty turning head to contralateral side, shoulder droop, weakness raising arm above horizontal

Associated symptoms (depending on lesion):

• Pulsatile tinnitus (paraganglioma)
• Hearing loss (middle ear involvement)
• Headache
• Weight loss (malignancy)

Physical Examination

Cranial nerve IX: Reduced gag reflex (afferent limb), loss of sensation in posterior pharynx, decreased taste on posterior tongue

Cranial nerve X: Uvula deviation to contralateral side, ipsilateral palatal droop, pooling of secretions, vocal fold paralysis on laryngoscopy

Cranial nerve XI: Weakness of sternocleidomastoid, trapezius weakness (shoulder droop, scapular winging), muscle atrophy in chronic cases

Otoscopy: May show pulsatile red mass behind tympanic membrane ("rising sun" sign) in glomus tumors; may be normal if lesion is intracranial

Additional examination: Hypoglossal nerve (XII) function to distinguish from Collet-Sicard Syndrome; Horner syndrome evaluation (if sympathetic chain involved, consider Villaret Syndrome)

Laboratory Tests

Endocrine studies (if paraganglioma suspected):

• 24-hour urine catecholamines: Elevated in catecholamine-secreting paragangliomas
• Plasma free metanephrines: Screen for catecholamine-secreting tumor
• Genetic testing: SDH mutations in familial paraganglioma (recommended for all paraganglioma patients)

Imaging

Imaging Characteristics by Tumor Type

Different jugular foramen tumors have characteristic imaging features that aid in differential diagnosis:

Imaging Characteristics of Jugular Foramen Tumors

Feature	Paraganglioma	Schwannoma	Meningioma
Bone changes	Permeative destruction	Smooth expansion, scalloped margins, sclerotic rim	Centrifugal infiltration, permeative-sclerotic
T1 signal	Isointense	Hypointense	Isointense
T2 signal	"Salt and pepper" (flow voids)	Hyperintense	Isointense to hyperintense
Enhancement	Intense, homogeneous	Strong, homogeneous	Intense with dural tail (100%)
Flow voids	Present (characteristic)	Absent	Absent
Extension pattern	Superolateral into middle ear	Intraosseous, dumbbell	Skull base infiltration
DCE-MRI curve	Type 3 (rapid wash-in, washout)	Type 1 (progressive)	Type 1-2

Advanced MRI techniques:

• Dynamic contrast-enhanced MRI (DCE-MRI) using golden-angle radial sparse parallel (GRASP) imaging can differentiate paragangliomas from schwannomas with 100% accuracy based on wash-in and washout rates
• DCE-MRI parameters (particularly Ve) show area under curve of 0.89-1.00 for distinguishing these tumors

Digital subtraction angiography (DSA): Gold standard for vascular assessment; allows preoperative embolization; evaluates collateral circulation if carotid sacrifice considered

Differential Diagnosis

There are several named syndromes differentiating the various cranial nerve deficits that can result from skull base masses and lesions. These should be considered based on cranial nerve involvement.

• Collet-Sicard Syndrome
• Villaret Syndrome
• Tapia Syndrome
• Jackson Syndrome
• Schmidt Syndrome

These syndromes and their respective cranial nerve involvement are outlined in the table below.

Cranial Nerve Involvement in Skull Base Masses

Syndrome	CN IX	CN X	CN XI	CN XII	Sympathetics
Vernet Syndrome	✔	✔	✔
Collet-Sicard Syndrome	✔	✔	✔	✔
Villaret Syndrome	✔	✔	✔	✔	✔
Tapia Syndrome		✔	±	✔	±
Jackson Syndrome		✔	✔	✔
Schmidt Syndrome		✔	✔

Management

Treatment Selection Algorithm

Treatment selection should be individualized based on tumor type, patient age, comorbidities, symptoms, and bilateral disease status.

Stereotactic radiosurgery (SRS) preferred for:

• Elderly patients or significant comorbidities
• Bilateral disease or existing contralateral cranial neuropathies
• Tumors <3 cm
• SDHD-related paragangliomas (2023 Lancet consensus guidelines)
• Patient preference to avoid surgery

Surgery preferred for:

• Young patients with good functional status
• Symptomatic mass effect requiring decompression
• Failed radiation therapy
• Need for tissue diagnosis
• Catecholamine-secreting tumors

Observation may be appropriate for asymptomatic elderly patients, particularly given tumor doubling time of approximately 10 years.

Medical Management

Supportive care:

• Speech and swallowing therapy
• Aspiration precautions
• Feeding tube if severe dysphagia
• Voice therapy and phonation support

Stereotactic Radiosurgery

SRS has become a primary treatment option, not just for residual disease, with excellent tumor control and lower complication rates than surgery.

Paraganglioma outcomes with SRS:

• Overall tumor control: 95%
• Primary treatment tumor control: 92%
• 5-year tumor control: 98%
• 10-year tumor control: 94%
• Note: Late progression can occur beyond 10 years

Schwannoma outcomes with SRS:

• Tumor control: 98% (95% CI: 95-100%)
• Tumor shrinkage: 39%
• Cranial nerve function improvement: 62% (in patients with preexisting deficits)
• Important: New cranial nerve deficits occurred in 34% of patients

Surgery vs. SRS comparison for paragangliomas:

• Tumor control: Surgery 85% vs. SRS 93% (long-term recurrence: 15% vs. 7%)
• Complication rates: Surgery 29.6% vs. SRS 7.6% (p=0.0418)
• SRS shows significantly lower complication rates with similar tumor control

Important counseling point: Tumor volume reduction with SRS is slow; median time to shrinkage is 9 months, and 42% of cases require ≥12 months to demonstrate response.

Surgical Management

Modern Surgical Approaches

Endoscope-assisted techniques represent a key advancement in jugular foramen surgery:

• Gross total resection achieved in 86-100% of cases
• Endoscope identifies tumor remnants missed by microscopy in 40% of cases
• Allows visualization of surrounding structures for safer intraforaminal tumor removal
• Reduced permanent neurological deficits compared to microscopy alone

Infratemporal fossa approaches (Fisch classification):

• Type A: Limited intradural extension; facial nerve transposition; total resection in 72% with only 8% permanent lower CN dysfunction
• Type B: Greater intracranial extension
• Type C: Combined infratemporal and intracranial approaches
• Type D: Medial skull base extension

Suboccipital paracondylar-lateral cervical (SPCLC) approach:

• Gross total resection: 92.2% (64 patients)
• No mortality, no tracheostomy requirement
• Symptom improvement: hearing 62.5%, dysphagia 53-56%, hoarseness 54%

Hybrid approaches: Partial resection + adjuvant SRS increasingly used for large tumors to reduce surgical morbidity while maintaining tumor control.

Surgical Outcomes by Tumor Type

Schwannoma:

• Gross total resection: 80-93%
• Recurrence rate: 1.5-10% over 5-10 years
• Permanent lower cranial nerve dysfunction: 8-12%
• Quality of life improvement: 65% at long-term follow-up

Paraganglioma: Complete resection in 85-90% of cases with preoperative embolization; cranial nerve preservation challenging

CSF leak reduction: Vascularized muscle flap reconstruction reduces CSF leak from 8-13% to near 0%

Outcomes

Complications

From disease:

• Aspiration pneumonia
• Malnutrition
• Voice dysfunction
• Lower cranial neuropathy progression

From treatment:

• Additional cranial nerve deficits (most frequent surgical complication; 34% new deficits with SRS for schwannomas)
• Cerebrospinal fluid (CSF) leak (8-13% surgical, reduced with vascularized flap reconstruction)
• Hearing loss
• Stroke (if carotid involved)
• Facial nerve weakness

Prognosis

Paraganglioma:

• Slow-growing; tumor doubling time approximately 10 years
• Long survival even without treatment (observation reasonable for elderly)
• Malignancy rates by location:
  • Vagal paragangliomas: 16-19% (highest)
  • Carotid body: ~6%
  • Jugular/tympanic: <1% (extremely rare)
• SDHB mutation associated with higher malignancy risk

Schwannoma:

• Generally good prognosis with complete excision
• Gross total resection: 80-93%
• Recurrence rate: 1.5-10% over 5-10 years

Functional recovery after surgery:

• Hearing improvement: 62.5% of patients with preoperative impairment
• Dysphagia improvement: 53-56%
• Hoarseness improvement: 54%
• Recovery typically occurs within first 2 postoperative weeks for temporary deficits

Important: Long-term follow-up >10 years is essential to assess treatment efficacy given slow growth patterns and potential for late progression.